Crossref
Olverembatinib for the treatment of chronic myeloid leukemia in chronic phase
Annals of Blood · 2024-09 · 9 · 27-27
DOI: 10.21037/aob-24-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Blood, 2024-09. Verfasst von Emaan Ul Haque und 3 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Haque, E. U., Jabbour, E., Senapati, J., & Haddad, F. G. (2024). Olverembatinib for the treatment of chronic myeloid leukemia in chronic phase. Annals of Blood, 9, 27-27. https://doi.org/10.21037/aob-24-5
Vancouver
Haque EU, Jabbour E, Senapati J, Haddad FG. Olverembatinib for the treatment of chronic myeloid leukemia in chronic phase. Annals of Blood. 2024;9:27-27. doi:10.21037/aob-24-5
BibTeX
@article{Haque2024,
author = {Haque, Emaan Ul and Jabbour, Elias and Senapati, Jayastu and Haddad, Fadi G.},
title = {Olverembatinib for the treatment of chronic myeloid leukemia in chronic phase},
journal = {Annals of Blood},
year = {2024},
volume = {9},
pages = {27--27},
doi = {10.21037/aob-24-5}
}
EUVIMED